Meine Merkliste  

2.516 Aktuelle Fachpublikationen von Future Medicine

mit folgenden Suchkriterien:

High-sensitivity troponin: where are we now and where do we go from here?

24.10.2014 | Frederick K Korley; Allan S Jaffe, Biomarkers in Medicine, 2014

High-sensitivity troponin (hsTn) assays are used clinically in most parts of the world and are expected to be approved by the US FDA for clinical use in the USA soon. Clinical use of hsTn leads to improvements in the detection of myocardial injury, shorter time to ruling out acute myocardial ...


Pregnancy-associated plasma protein-A and the vulnerable plaque

24.10.2014 | Camilla H B Jespersen; Kirstine R Vestergaard; Morten Schou; Børge Teisner; Jens P Goetze; Kasper Iversen, Biomarkers in Medicine, 2014

For more than a decade, pregnancy-associated plasma protein-A (PAPP-A) has been examined for its relation to acute coronary syndrome (ACS) and the vulnerable plaque. This review summarizes the current knowledge of plasma PAPP-A in relation to nonpregnant individuals focusing on patients with ACS, ...


Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease

24.10.2014 | Marina Harutyunyan; Julia S Johansen; Naja D Mygind; Simon B Reuter; Jens Kastrup, Biomarkers in Medicine, 2014

Aim: The aim was to investigate the inflammatory biomarker YKL-40 as a monitor of myocardial ischemia in patients with coronary artery disease (CAD). Methods: A total of 311 patients with stable CAD were included. Blood samples were taken at baseline, the day after coronary angiography and/or ...


Cost–effectiveness of risk assessment and tailored treatment for peripheral arterial disease patients

24.10.2014 | Anil Vaidya; Manuela A Joore; Arina J ten Cate-Hoek; Hugo ten Cate; Johan L Severens, Biomarkers in Medicine, 2014

Aim: The objective of this study was to explore the cost–effectiveness of D-dimer biomarker and the societal value (headroom) of a hypothetical perfect biomarker for risk assessment and subsequent treatment stratification of prophylactic treatment for peripheral arterial disease (PAD). Patients & ...


Signal peptides: new markers in cardiovascular disease?

24.10.2014 | Chris J Pemberton, Biomarkers in Medicine, 2014

Proteins and peptides are well-documented as useful marker adjuncts to cardiovascular clinical decision-making. Most markers measured derive from a defined, stable proprotein region of their respective gene. However, a neglected portion of preproproteins known as the signal peptide (SP) is also ...


Novel serum biomarkers in pulmonary arterial hypertension

24.10.2014 | Neil McGlinchey; Martin K Johnson, Biomarkers in Medicine, 2014

Pulmonary arterial hypertension (PAH) remains a difficult-to-treat condition with high mortality. Biomarkers are utilized to aid with diagnosis, prognostication and response to treatment. A clinically useful and PAH-specific single biomarker that is easy to measure remains elusive. This is in ...


Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens

23.10.2014 | Garyphallia Poulakou; Matteo Bassetti; Elda Righi; George Dimopoulos, Future Microbiology, 2014

ABSTRACT  The spread of multidrug-resistant, extensively drug-resistant and pan-drug-resistant pathogens is causing an unprecedented public health crisis. The limited current therapeutic options led to the revival of two ‘old’ antibiotics – colistin and fosfomycin – for which a better ...


Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action

23.10.2014 | Hao Tang; Olga O McGowan; Gavin P Reynolds, Pharmacogenomics, 2014

The receptor pharmacology of many antipsychotic drugs includes actions at various serotonin (5-hydroxytryptamine [5-HT]) receptors. The 5-HT neurotransmitter system is thought to be involved in many of the consequences of treatment with antipsychotic drugs, including both symptom response, ...


Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers

23.10.2014 | Aurea Lima; Hugo Sousa; Joaquim Monteiro; Rita Azevedo; Rui Medeiros; Vitor Seabra, Pharmacogenomics, 2014

Methotrexate (MTX) is used in low doses to treat a variety of diseases. Although the mechanism responsible for its therapeutic action is unknown, MTX membrane transport proteins (influx and/or efflux) can be major determinants of pharmacokinetics, adverse drug reactions and clinical response ...


Do variations in the ITPA gene determine the risk of hepatitis C virus relapse?

23.10.2014 | Jesper Waldenström; Kristina Nyström; Martin Lagging, Future Microbiology, 2014

Future Microbiology September 2014, Vol. 9, No. 9, Pages 1009-1012.


Seite 1 von 252
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.